Recent innovations in type 1 diabetes treatment focus on disease-modifying immunotherapies like teplizumab to delay clinical onset, advanced continuous glucose monitoring systems paired with automated insulin delivery loops, and cutting-edge cell therapies involving encapsulated islet cell transplants or stem-cell-derived beta cell replacements intended to restore natural insulin production.